PrEP Care Continuum Among Certain Patient Populations in the United States
There is an increased need for PrEP uptake among transgender women, men who have sex with men, and transgender women of color in the United States.
CROI 2020
Raltegravir-Based ART Shows Lower Rates of Hepatoxicity
Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).
CMV-Specific Immune Response in Advanced HIV Infections
Cytomegalovirus (CMV) viremia is suppressed after the start of antiretroviral treatment (ART) without specific anti-CMV treatment.
Two-Drug Regimens Comparable With Three-Drug Regimens for HIV
Two-drug regimens are shown to be comparable with 3-drug regimens as viable clinical treatment options for HIV.
The Renal-Bone Axis and ART in Adolescents and Elderly With HIV
Particular antiretroviral therapy (ART) regimens may decrease bone mass density (BMD) in both adolescents and older people living with HIV (PWHIV).
Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.
Long-Acting Cabotegravir + Rilpivirine Noninferior to Standard Treatment for HIV
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.
Dried Blood Spot Viral Load More Accurate Than Plasma Viral Load in HIV?
Dried blood spot viral load may be more accurate and useful than plasma viral load for patients with HIV in settings with limited resources.
Buprenorphine Treatment Linked to Decreased HIV RNA Viral Loads
Buprenorphine treatments for opioid use disorder among people living with HIV demonstrated beneficial effects in terms of viral load.
Cardiac Events Significantly Higher With TAF vs TDF Treatment for HIV
The occurrence of cardiac events in a cohort of patients with HIV was significantly higher in patients treated with tenofovir-alafenamide.
Pulmonary Tuberculosis Enhances HIV-1 Antibody Responses
Active infection with tuberculosis enhances anti-HIV-1 antibody response.
Sofosbuvir/Velpatasvir Combination Therapy Efficacious in HCV/HIV Coinfection
Combination sofosbuvir/velpatasvir treatment can be highly efficacious in treating hepatitis C virus (HCV) infection in patients coinfected with HIV.
Increased Cardiovascular Disease Risk Among Youth Living With HIV
Research results revealed increased risks for cardiovascular disease and insulin resistance among young individuals with HIV.
Point-of-Care Test Shows Early Promise for Diagnosing Neurosyphilis
The point-of-care Dual Path Platform (DPP®) assay may be an inexpensive tool for the diagnosis of neurosyphilis.
Hepatic Steatosis in People With HIV, People who Use Intravenous Drugs
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
Study Findings Suggestive of Second HIV Cure Case: The London Patient
A British man, known as the London patient, may be the second person to be cured of HIV.
Transmission of DAA Resistance Inhibits Cure Rates Among HIV/HCV Coinfected MSM
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
Three Years of Persistent Undetectable HIV Viremia in a Four-Year-Old Child
A child with intrauterine-acquired HIV who received antiretroviral therapy (ART) at 33 hours after birth through age 13 months showed persistent undetectable HIV viremia more than 3 years after discontinuing ART.
Telmisartan Adjunct Treatment May Reduce CNS Inflammation During Acute HIV
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Two-Drug Antiretroviral Therapy May Decrease Resistance, Toxicity in PLWHIV
Effective 2-drug regimens may potentially decrease long-term exposure and toxicity with HIV-1 antiretroviral therapy.
Want to read more?
Please login or register first to view this content.
Next post in CROI 2020
